AXSM
Axsome Therapeutics Inc
179.30$
-1.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +91.0% | +44.7% | +288.1% | -50.6% | +23.8% | +23.8% | +4.8% | +16.2% | +20.2% | +13.4% | +2.3% | +23.5% | +14.0% | +14.6% | -2.4% | +14.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +3,232.0% | +8.0% | +2.6% | +1.4% | +215.4% | +95.7% | +19.1% | +229.8% | -39.1% | +42.0% | +13.0% | -14.7% | +27.9% | +4.7% | +24.6% | -6.9% | +37.4% | -11.4% | +3.5% | +19.4% | -7.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +90.4% | +48.0% | +294.1% | -51.6% | +21.8% | +25.1% | +7.1% | +15.2% | +21.8% | +12.4% | +3.2% | +22.3% | +16.5% | +15.5% | -3.9% | +16.1% | – | |
| – | +4.3% | +3.1% | -16.3% | -10.7% | +0.5% | +5.8% | +16.8% | +8.8% | +18.4% | +6.3% | +44.7% | +43.9% | +21.3% | +43.3% | -61.7% | +40.3% | +17.5% | -4.5% | -12.6% | -9.1% | +4.6% | -8.7% | +25.5% | -5.8% | -1.2% | +21.1% | +15.7% | +39.8% | +7.1% | +19.6% | +35.4% | -9.0% | +21.2% | -18.6% | +10.6% | -18.9% | +21.5% | +8.0% | -12.2% | – | |
| – | +11.0% | -7.3% | +3.4% | +4.8% | +6.8% | +23.6% | +1.2% | -9.7% | +4.4% | +22.6% | -13.2% | +27.3% | +67.8% | -4.8% | +45.6% | -12.5% | +63.6% | +5.8% | +49.1% | +23.8% | -6.9% | +36.5% | +21.2% | +31.2% | +139.1% | -46.0% | -1.1% | +5.5% | +13.8% | +19.6% | -2.3% | +30.5% | -8.9% | +38.7% | -21.9% | +15.4% | +55.6% | +9.3% | +12.5% | – | |
| – | +5.8% | +0.6% | -12.0% | -6.7% | +2.3% | +11.2% | +11.5% | +3.2% | +14.6% | +10.3% | +29.0% | +40.9% | +28.9% | +33.0% | -45.3% | +18.8% | +31.3% | +0.4% | +10.8% | +8.3% | -2.4% | +17.4% | +22.8% | +21.9% | +43.0% | +13.9% | +14.7% | +5.8% | +43.3% | -16.3% | +15.6% | +1.1% | +13.8% | -6.8% | +2.8% | +18.4% | +3.9% | +12.5% | +6.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,244.0% | +81.8% | +3.3% | +2.9% | -0.8% | -7.4% | -7.3% | -7.3% | -8.2% | -12.0% | +43.4% | +4.4% | +15.6% | -98.1% | +7,397.7% | +0.5% | +167.5% | -3.9% | +1.5% | +2.7% | -7.3% | -1.8% | +68.1% | +6.8% | -45.1% | +71.2% | +20.6% | -72.3% | -7.3% | +54.1% | +20.1% | +52.3% | +11.7% | +10.0% | -24.6% | -38.9% | +4.6% | +1.1% | +30.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -100.0% | – | – | – | +52.3% | -11.0% | -177.5% | – | – | – | – | -101.2% | – | – | – | -101.4% | – | – | – | – | -1.8% | +4.0% | +72.5% | +129.1% | -53.3% | -123.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.